Journals / Turkish Journal of Medical Sciences / 2017 / Cilt: 47 - Sayı: 5

The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience

Pages
1307–1314
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A complete response was achieved in 52.5% and partial response (

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aim: Since the majority of the IgG4-related disease (IgG4-RD) patients in the literature are from the Far East and the United States, there is a lack of large series from other parts of the world.
📊
Key Findings & Data:We aimed to identify the clinical characteristics and outcome of Turkish IgG4-RD patients from a tertiary center.
💡
Conclusion & Impact:A complete response was achieved in 52.5% and partial response (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Background/aim: Since the majority of the IgG4-related disease (IgG4-RD) patients in the literature are from the Far East and the United States, there is a lack of large series from other parts of the world. We aimed to identify the clinical characteristics and outcome of Turkish IgG4-RD patients from a tertiary center. Materials and methods: Fifty-two patients classified as having definite IgG4-RD according to comprehensive diagnostic criteria were included in the study. Patients not fulfilling the definite criteria due to lack of pathologic specimen and/or serum IgG4 levels were excluded (n = 47). Clinical, laboratory, and histopathological features and treatment approaches were analyzed. Results: Median age at diagnosis was 51.1 years and sex predominance was not observed (male/female: 26/26). Median follow-up duration was 18 (IQR 25 75: 8 35) months. Retroperitoneal fibrosis was the most frequent presentation. Twenty-four (46.1%) patients had localized involvement. Corticosteroids were the mainstay of treatment (92.5%). Rituximab had been used for cases resistant to previous treatment or with relapses in 19 (47.5%) patients. A complete response was achieved in 52.5% and partial response (

🔖

Cite This Article

KILIÇ, L., BÖLEK, E. Ç., KARADAĞ, Ö., AKDOĞAN, B., KALYONCU, U., AYHAN, E. A., ERDEN, A., BİLGEN, Ş. Ş. A., KİRAZ, S., ERTENLİ, A. İ., SARI, A., BAYDAR, D., ARMAĞAN, B., AKDOĞAN, A., HAZIROLAN, T. (2022). The clinical features and outcomes of Turkish patients with IgG4-related disease:a single-center experience. Turkish Journal of Medical Sciences, Cilt: 47 - Sayı: 5, 1307–1314. https://ajindex.com/articles/610596

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Stone JH, Zen Y, Deshpande V. IgG4 related disease. N Engl J Med 2012; 366: 539-551
  2. Brito-Zerón P, Ramos-Casals M, Bosch X, Stone JH. The clinical spectrum of IgG4-related disease. Autoimmun Rev 2014; 13: 1203-1210
  3. Mayo, Sekiguchi H, Horie R, Kanai M. IgG4-related disease: retrospective analysis of one hundred sixty-six patients. Arthritis Rheumatol 2016; 68: 2290-2299
  4. Wallace ZS, Deshpande V, Mattoo H, Mahajan VS, Kulikova M, Pillai S, Stone JH. IgG4-related disease: clinical and laboratory features in 125 patients. Arthritis Rheumatol 2015; 67: 2466- 2475
  5. Soliotis F, Mavragani CP, Plastiras SC, Rontogianni D, Skopouli FN, Moutsopoulos HM. IgG4-related disease: a rheumatologist’s perspective. Clin Exp Rheumatol 2014; 32: 724-727
  6. Szántó A, Nagy G, Molnár CS, Griger Z, Tarr T, Zeher ME. Description of patients with IgG4-related disease from a Hungarian centre. Scand J Rheumatol 2014; 43: 334-337
  7. Huggett MT, Culver EL, Kumar M, Hurst JM, Rodriguez-Justo M, Chapman MH, Johnson GJ, Pereira SP, Chapman RW, Webster GJ et al. Type 1 autoimmune pancreatitis and IgG4- related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol 2014; 109: 1675-1683
  8. Agaimy A, Weyand M, Strecker T. Inflammatory thoracic aortic aneurysm (lymphoplasmacytic thoracic aortitis): a 13-year-experience at a German heart center with emphasis on possible role of IgG4. Int J Clin Exp Pathol 2013; 6: 1713-1722
  9. Ebbo M, Daniel L, Pavic M, Sève P, Hamidou M, Andres E, Burtey S, Chiche L, Serratrice J, Longy-Boursier M et al. IgG4- related systemic disease: features and treatment response in a French cohort: results of a multicenter registry. Medicine (Baltimore) 2012; 91: 49-56
  10. Fernández-Codina A, Martínez-Valle F, Pinilla B, López C, DeTorres I, Solans-Laqué R, Fraile-Rodríguez G, CasanovasMartínez A, López-Dupla M, Robles-Marhuenda Á et al. IgG4- related disease: results from a multicenter Spanish registry. Medicine (Baltimore) 2015; 94: e1275
  11. Campochiaro C, Ramirez GA, Bozzolo EP, Lanzillotta M, Berti A, Baldissera E, Dagna L, Praderio L, Scotti R, Tresoldi M et al. IgG4-related disease in Italy: clinical features and outcomes of a large cohort of patients. Scand J Rheumatol 2016; 45: 135- 145
  12. Martínez-Valle F, Fernández-Codina A, Pinal-Fernández I, Orozco-Gálvez O, Vilardell-Tarrés M. IgG4-related disease: evidence from six recent cohorts. Autoimmun Rev